These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 32281092

  • 1. Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
    Ghodsirad MA, Pirayesh E, Akbarian R, Javanmard B, Kaghazchi F, Tavakoli M, Fattahi K.
    Urol J; 2020 Jun 23; 17(4):374-378. PubMed ID: 32281092
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jun 23; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 23; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 4. High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients.
    Watabe T, Uemura M, Soeda F, Naka S, Ujike T, Hatano K, Sasaki H, Kamiya T, Shimosegawa E, Kato H, Cardinale J, Tateishi U, Nonomura N, Giesel FL.
    Ann Nucl Med; 2021 Apr 23; 35(4):523-528. PubMed ID: 33661475
    [Abstract] [Full Text] [Related]

  • 5. Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer.
    Burgard C, Rosar F, Larsen E, Khreish F, Linxweiler J, Marlowe RJ, Schaefer-Schuler A, Maus S, Petto S, Bartholomä M, Ezziddin S.
    Cancer Imaging; 2024 Oct 07; 24(1):132. PubMed ID: 39375762
    [Abstract] [Full Text] [Related]

  • 6. Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
    Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, Kraeber-Bodéré F.
    Prostate; 2019 Sep 07; 79(13):1514-1522. PubMed ID: 31421657
    [Abstract] [Full Text] [Related]

  • 7. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
    Veliev EI, Tomilov AA, Goncharuk DA, Bogdanov AB, Golubtsova EN.
    Urologiia; 2018 Jul 07; (3):105-110. PubMed ID: 30035428
    [Abstract] [Full Text] [Related]

  • 8. SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with Recurrent Prostate Cancer.
    Sergieva S, Mangaldgiev R, Dimcheva M, Nedev K, Zahariev Z, Robev B.
    Nucl Med Rev Cent East Eur; 2021 Jul 07; 24(2):70-81. PubMed ID: 34382671
    [Abstract] [Full Text] [Related]

  • 9. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Prostate; 2018 Jan 07; 78(1):54-63. PubMed ID: 29105797
    [Abstract] [Full Text] [Related]

  • 10. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer.
    Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M.
    Clin Nucl Med; 2016 Sep 07; 41(9):e397-402. PubMed ID: 27276206
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
    Carvalho J, Nunes P, Da Silva ET, Silva R, Lima J, Quaresma V, Figueiredo A.
    Arch Ital Urol Androl; 2021 Mar 18; 93(1):21-25. PubMed ID: 33754603
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May 18; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 16. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug 18; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 17. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.
    Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446
    [Abstract] [Full Text] [Related]

  • 18. Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence.
    Cantiello F, Crocerossa F, Russo GI, Gangemi V, Ferro M, Vartolomei MD, Lucarelli G, Mirabelli M, Scafuro C, Ucciero G, De Cobelli O, Morgia G, Damiano R, Cascini GL.
    Clin Genitourin Cancer; 2018 Oct 10; 16(5):385-391. PubMed ID: 29937067
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.
    J Nucl Med; 2015 Aug 10; 56(8):1185-90. PubMed ID: 26112024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.